Development of PIN and prostate adenocarcinoma cell lines: a model system for multistage tumor progression.
Existing prostate cancer cell lines have been derived from late stages of human prostate cancer. In this paper, we present two cell lines generated from prostatic intraepithelial neoplasia (PIN), the precursor lesion for prostate adenocarcinoma. Pr-111 and Pr-117 were established from PIN lesions that developed in the C3(1)/Tag transgenic model of prostate cancer. Pr-111 and Pr-117 cells express simian virus 40 large T antigen (SV40 Tag) and are immortalized in culture, distinguishing them from normal prostate cells. The growth rates of these two cell lines are quite different; with Pr-111 cells growing much more slowly (doubling time approximately 40 hours) compared to Pr-117 cells (doubling time approximately 22 hours), and also show significantly different growth rates in different media. Both prostate cell lines express cytokeratin and androgen receptor (AR) with Pr-111 cells demonstrating androgen-dependent growth and Pr-117 cells exhibiting androgen-responsive growth characteristics. Athymic nude mice injected with Pr-111 cells either do not develop tumors or develop tumors after a long latency period of 14 weeks. Pr-117 cells, however, develop tumors by 3 to 6 weeks, suggesting that Pr-117 cells represent a later stage of tumor progression. These two novel cell lines will be useful for studying early stages of prostate tumor development and androgen responsiveness.
Soares
Colin R
CR
Department of Biology, Boise State University, Boise, ID 83725, USA.
Shibata
Masa-Aki
MA
Green
Jeffrey E
JE
Jorcyk
Cheryl L
CL
D016475:3T3 Cells; D000230:Adenocarcinoma / Q000378:metabolism / Q000473:pathology*; D000728:Androgens / Q000494:pharmacology; D000818:Animals; D000952:Antigens, Polyomavirus Transforming / Q000378:metabolism; D015153:Blotting, Western; D018929:Cell Culture Techniques / Q000379:methods; D002455:Cell Division / Q000187:drug effects; D003094:Collagen; D004195:Disease Models, Animal; D018450:Disease Progression; D004338:Drug Combinations; D005455:Fluorescent Antibody Technique; D007797:Laminin / Q000494:pharmacology; D008297:Male; D051379:Mice; D008819:Mice, Nude; D008822:Mice, Transgenic; D009368:Neoplasm Transplantation; D019048:Prostatic Intraepithelial Neoplasia / Q000378:metabolism / Q000473:pathology*; D011471:Prostatic Neoplasms / Q000378:metabolism / Q000473:pathology*; D011509:Proteoglycans; D011944:Receptors, Androgen / Q000378:metabolism; D014407:Tumor Cells, Cultured; D014746:Vimentin / Q000378:metabolism
D000728:Androgens; D000952:Antigens, Polyomavirus Transforming; D004338:Drug Combinations; D007797:Laminin; D011509:Proteoglycans; D011944:Receptors, Androgen; D014746:Vimentin; C059485:matrigel; D003094:Collagen